Moreover, when compared with other chemotherapeutic agents commonly used in BCR/ABL ALL human patients, including cyclophosphamide, doxorubicin, cytarabine, and vincristine, CY's survival extension was also superior to these drugs (Fig4D). The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.